Only 13 states currently allow Medicaid to cover GLP-1 agonist drugs for obesity treatment, highlighting a significant gap in ...

Ozempic is making its presence known on menus, and the forecast for dumplings is 100% sunshine.

The company said that, based on a pharmacokinetic study, it has plumped for a once-daily, modified-release formulation of GLP-1 agonist danuglipron ... which has a long list of candidates in ...

Novo said supply of Wegovy and Ozempic is in good shape after the drugs were removed from the FDA’s shortage list last week.

which are both based on the GLP-1 receptor agonist. Wegovy and Ozempic remain on the FDA's shortages list, despite strenuous efforts by Novo Nordisk to ramp up its production capacity for semaglutide.

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

Weight loss drugs like Ozempic and Wegovy may provide strong relief from severe osteoarthritis knee pain, new research finds.

For example, a GLP-1 receptor agonist, like Wegovy (semaglutide), acts like the GLP ... However, these are the manufacturer list prices, meaning the pharmacy's actual retail cost might be higher.

The company is still 'evaluating' the price of the drug, but is confident that the price-sensitive Indian population will be able to afford it, Novo's India Managing Director Vikrant Shrotriya said ...

Supplements promising similar results to Ozempic have taken over social media, but the TGA and health experts have concerns.

The head of the company that makes the diabetes and obesity drugs Ozempic and Wegovy has warned that compounded versions of ...

New guidelines for diabetes treatment, mpox research, and healthcare system improvements discussed in comprehensive health ...